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ABSTRACT  
 
Background & Aims: Approaches to risk stratification for patients with primary biliary cirrhosis (PBC) 
are limited, single-center based, and often dichotomous. We aimed to develop and validate a better 
model for determining prognoses of patients with PBC.  
 
Methods: We performed an international, multicenter meta-analysis of 4119 patients with PBC 
treated with ursodeoxycholic acid (UDCA) at liver centers in 8 European and North American 
countries. Patients were randomly assigned to derivation (n=2488, 60%) and validation cohorts 
(n=1631, 40%). A risk score (GLOBE score) to predict transplantation-free survival was developed and 
validated with univariate and multivariable Cox regression analyses using clinical and biochemical 
variables obtained after 1 y UDCA therapy. Risk score outcomes were compared with the survival of 
age-, sex-, and calendar time-matched members of the general population. The prognostic ability of 
the GLOBE score was evaluated alongside those of the Barcelona, Paris-1, Rotterdam, Toronto, and 
Paris-2 criteria.  
 
Results: Age (hazard ratio [HR], 1.05; 95% confidence interval [CI], 1.04–1.06; P<.0001); levels of 
bilirubin (HR, 2.56; 95% CI, 2.22–2.95; P<.0001), albumin (HR, 0.10; 95% CI, 0.05–0.24; P<.0001), and 
alkaline phosphatase (HR, 1.40; 95% CI, 1.18–1.67; P=.0002); and platelet count (HR/10 units 
decrease, 0.97; 95% CI, 0.96–0.99; P<.0001) were all independently associated with death or liver 
transplantation (C statistic derivation, 0.81; 95% CI, 0.79–0.83, and validation cohort, 0.82; 95% CI, 
0.79–0.84). Patients with risk scores >0.30 had significantly shorter times of transplant-free survival 
than matched healthy individuals (P<.0001). The GLOBE score identified patients who would survive 
for 5 y and 10 y (responders) with positive predictive values of 98% and 88%, respectively. Up to 22% 
and 21% of events and non-events, respectively, 10 y after initiation of treatment were correctly 
reclassified in comparison with earlier proposed criteria. In subgroups of patients <45 y, 45–52 y, 52–
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58 y, 58–66 y, and ≥66 y old, age-specific GLOBE-score thresholds beyond which survival significantly 
deviated from matched healthy individuals were –0.52, 0.01, 0.60, 1.01 and 1.69, respectively. 
Transplant-free survival could still be accurately calculated by the GLOBE score with laboratory 
values collected at 2–5 y after treatment. 
 
Conclusions: We developed and validated scoring system (the GLOBE score) to predict transplant-
free survival of UDCA-treated patients with PBC. This score might be used to select strategies for 
treatment and care.  
 
KEYWORDS: cholestasis; autoimmune liver disease; prognosis; predictive factor 
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INTRODUCTION 
 
Primary biliary cirrhosis (PBC) is the most common of the autoimmune liver diseases, with 1 in 1000 
women over the age of 40 affected.
1
 Prognosis largely depends on the development of liver cirrhosis 
and its complications.
2
 Presently, treatment with ursodeoxycholic acid (UDCA) represents the global 
standard of care,
2, 3
 and can delay histological progression
4-6
 and can improve long-term survival.
7, 8
 
However, UDCA is not an uniformly effective drug and the prognosis of patients insufficiently 
responding to treatment is markedly worse compared with the general population.
9
 Reliable 
identification of such individuals is of key importance to clinical management, particularly for 
selecting those who could benefit from additional second-line medical therapies, but equally for 
identification of patients at low risk of developing end-stage liver disease.  
A number of existing stratification tools, using biochemical liver tests applied after one or 
two years of UDCA exposure, will readily identify patients with or without sufficient treatment 
response.
9-13
 Paris-1 criteria is generally considered as the one with best predictability of transplant-
free survival as validated in large studies, such as the UK-PBC consortium and our own group.
11, 14-16
 
However, Paris-1 and other criteria were all based on dichotomized variables, potentially leading to 
loss of important predictive information. And even more important there is a relatively high 
disagreement between the different criteria in classifying someone among low- and high risk 
groups.
17
  
The Global PBC Study Group has representative data from an international PBC research 
collaboration that has already evaluated biochemical surrogates of disease progression and liver 
cancer risk.
16, 18
 The aim of present study was to utilise our unique dataset, alongside representative 
healthy population data, to develop a new unifying score with optimal ability to identify UDCA 
treated patients with an insufficient treatment effect, based on readily obtainable, biochemical and 
clinical variables. 
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METHODS 
 
Study population and design 
Patients were derived from the Global PBC Study Group database. This study group is an 
international and multicenter collaboration between 15 liver centers from 8 North American and 
European countries, which combined individual patient data from major long-term follow-up 
cohorts. Most cohorts included prospectively collected follow-up data. All patients had an 
established diagnosis of PBC
2, 3
 and characteristics of the study population have been previously 
described elsewhere.
18
 For the current study only those patients treated with UDCA were included. 
Patients were excluded if follow-up data were insufficient or unavailable, the start date of treatment 
or the exact date of major clinical events was unknown or in case of concomitant liver disease. 
Collected clinical and laboratory data included gender, age, PBC diagnosis, liver histology, treatment 
(type of medication, dosage and duration), duration and last date of follow-up, baseline 
antimitochondrial antibody status, baseline and yearly laboratory values (serum alkaline 
phosphatase, total bilirubin, albumin, aspartate aminotransferase (AST), alanine aminotransferase 
(ALT) and platelets and outcomes (death and cause of death, liver transplantation, hepatocellular 
carcinoma, ascites and variceal bleeding).  
 
Ethical approval 
This study was conducted in accordance with the protocol and the principles of the Declaration of 
Helsinki. The protocol was approved by the Institutional Research Board of the corresponding 
center, and at each participating center, in accordance with local regulations.  
 
Statistical analysis 
The study population was divided into a two cohorts, a derivation series comprising a randomly 
selected group of 2488 patients (60%), with the remainder serving as of a validation cohort (n=1631, 
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40%). Follow-up commenced at the start of UDCA therapy. Clinical outcome consisted of a 
composite endpoint of liver transplantation and all-cause mortality with the first event considered. 
Patients failing to reach a clinical endpoint were censored at time of last follow-up.  
For development of our risk score only easily and readily available clinical and laboratory 
variables were considered: sex, baseline age, and serum bilirubin, alkaline phosphatase, AST, ALT, 
albumin, platelet count, AST/ALT ratio, and AST to platelet ratio index (APRI) at one year follow-up. 
Where indicated, continuous variables underwent natural logarithmic transformation to correct for 
non-linearity. Multiple imputation was also applied to account for missing data wherein ten 
complete datasets were constructed by imputing missing values (SAS Proc MI, MCMC method; SAS 
9.3).
19
  
Time-to-event analysis was conducted using univariate and multivariable cox proportional 
hazard regression, and a final model was selected by comparing the goodness of fit criteria (Akaike 
Information Criteria and maximum-likelihood estimation). The final model was checked for potential 
confounding factors and interactions between the included variables. A penalised maximum 
likelihood estimation was used to account for over fitting of the model.
20
 
21
  
A prognostic index (GLOBE score) was calculated with the beta coefficients of variables 
included in the final penalized multivariable model, along with a baseline survival estimate S0(t), 
t=time. The GLOBE score was centered on the median in the derivation set.     
The overall discriminative ability of the GLOBE score was measured with C statistic in both 
the derivation and validation cohort. To visualise the discriminate ability Kaplan-Meier curves were 
plotted of 5 risk groups according to the 10
th
, 40
th
, 60
th
 and 90
th
 percentiles of the GLOBE score.  
Calibration of the GLOBE score was tested within the validation set.
22
 The calibration slope 
was calculated by estimating the regression coefficient on the GLOBE score. The necessity of 
recalibration was further tested by performing a Cox regression analysis on the variables included in 
the final model and including the GLOBE score with the regression coefficient constrained to 1. A 
good model fit was reached when the joint test of all beta coefficients did not significantly differ 
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from 0. The accuracy of the baseline survival estimate S0(t) was investigated by comparing the 
predicted survival probabilities of the 5 risk groups as defined above in the validation set with the 
observed Kaplan-Meier survival probabilities. 
In order to identify patients in whom prognosis significantly deviates from normal, the score 
was calculated beyond which prognosis was significantly worse than of a normal population. To 
determine this threshold, survival of patients with GLOBE scores below the tenth percentile was 
compared with that of an age-, sex- and calendar time matched Dutch population. During 
subsequent steps patients with scores within the next ten percentiles were added to the population 
and calculations were repeated until survival significantly deviated from that of the matched normal 
population (non-responders). Data of the matched population, a population with a life-expectancy 
comparable with that of the other participating countries, were retrieved from a Dutch registry 
(Statistics Netherlands, www.cbs.nl). The performance of the GLOBE score using this threshold was 
assessed with sensitivity, specificity, negative predictive value and positive predictive value at 5- and 
10-year follow-up. For this purpose a GLOBE score below the aforementioned threshold was 
considered as a positive test and the absence of adverse outcome was considered as an event.  
The overall predictive performance of previously reported tools (the Barcelona,
9
 Paris-1,
10
 
Rotterdam,
11
 Toronto
12
 and Paris-2 criteria
13
) was assessed with C statistic. To quantify the 
improvement in discriminative ability the net reclassification improvement (NRI) for both events and 
non-events
23, 24
 during the first 5 and 10 years follow-up was calculated.    
All analyses were 2 sided. P <.05 was considered statistically significant if not otherwise 
specified. Statistical analyses were performed with IBM SPSS Statistics 22.0 (SPSS Inc, Chicago, IL, 
USA) and SAS 9.3 (SAS institute, Cary, NC, USA). 
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RESULTS 
 
Clinical characteristics of the derivation cohort 
The derivation cohort consisted of 2488 subjects with PBC, with a median age of 54.6 years at the 
time of diagnosis (Table 1).  During a median follow-up of 7.8 years (interquartile range (IQR) 4.0-
12.1) 558 patients reached a clinical endpoint; 369 patients died and 189 patients underwent liver 
transplantation (center specific characteristics are described in Supplementary Table 1). The 5-, 10- 
and 15-year transplant-free survival rates were 90.0%, 77.5% and 65.6% respectively, as shown in 
Figure 1.  
 
Construction of the GLOBE score 
Following univariate Cox regression analyses older age at start of UDCA therapy, male sex, elevated 
serum bilirubin, alkaline phosphatase, AST and ALT levels, lower serum albumin levels and 
thrombocytopenia and higher AST/ALT and APRI ratios after one year of UDCA therapy were all 
associated with higher risk of liver transplantation or death (Table 2). The final penalized 
multivariable model comprised age, bilirubin, albumin, alkaline phosphatase and platelet count as 
independent predictors of liver transplantation or death (Table 2). No significant interactions were 
found between these variables (Supplementary Table 2).  
 
The GLOBE score was calculated as follows:  
GLOBE score = (0.044378 * age at start of UDCA therapy + 0.93982 * LN(bilirubin times the upper 
limit of normal (ULN) at 1 year follow-up)) + (0.335648 * LN(alkaline phosphatase times the ULN at 1 
year follow-up)) – 2.266708 * albumin level times the lower limit of normal (LLN) at 1 year follow-up 
– 0.002581 * platelet count per 10
9
/L at 1 year follow-up) + 1.216865.  
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The distribution of the GLOBE score is plotted in Supplementary Figure 1. The baseline survival 
curve at the mean GLOBE score S0(t) was: 0.9652, 0.9385, 0.8429, 0.7361 at 3-, 5-, 10- and 15-year 
follow-up respectively. The survival S(t) for any given patients was then calculated by S(t) = S0(t) 
exp(GLOBE score)
. 
 
Example:  
For a 50-year old patient with a bilirubin level of 1 time the ULN, an alkaline phosphatase level of 3 
times the ULN, an albumin level of 1.5 time the LLN and a platelet count of 250 per 10
9
/L:  
GLOBE score = 0.64; transplant-free survival at 5-year, S(5) = 88.6% and at 10-year, S(10) = 72.2%.            
 
The overall predictive ability of the GLOBE score for transplantation or death, calculated with C 
statistic, was 0.81 (95% CI, 0.79-0.83).  
  
Validation of the GLOBE score 
The clinical characteristics of the validation cohort (n=1631) are described in Table 1. During a 
median follow-up time of 7.5 years (IQR 3.8-11.8) 328 patients reached a clinical endpoint; 197 died 
and 131 received a liver transplant (center specific characteristics are described in Supplementary 
Table 1). The 5-, 10- and 15-year transplant-free survival rates were 90.0%, 79.6% and 66.3% 
respectively and not significantly different from those observed in the derivation cohort (Figure 1). 
 A comparable overall discriminative ability was found as in the derivation cohort (C statistic 
0.82, 95% CI 0.79-0.84). To explore to what extent the GLOBE score might be influenced by the 
imputation process for missing variables, the discriminative ability of the GLOBE score was 
additionally tested in cases with complete data. These analysis showed comparable results (C 
statistic derivation cohort: 0.82, 95% CI 0.78-0.86 and validation: 0.83, 95% CI 0.79-0.86).  
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The discriminative ability of the GLOBE score was visualised by plotting the transplant-free 
survival curves for 5 risk groups according to the 10
th
, 40
th
, 60
th
 and 90
th
 percentiles of the score 
(Figure 2). Good separation was shown for the survival curves of the 5 risk groups.   
There was a good agreement between the curves in the derivation and validation cohort as 
shown in Figure 2, with a good model fit (calibration slope, P value=0.64). No re-calibration of the 
GLOBE score was necessary, when calculating the regression coefficient on the prognostic index (P 
value=0.22). Further, the predicted survival probabilities corresponded well with the observed 
survival probabilities (Supplementary Table 3).   
  
Application of the GLOBE score 
An overall threshold was determined for the GLOBE score in the derivation cohort beyond which 
prognosis of patients significantly deviated from a normal life-expectancy (non-responders). Patients 
with a GLOBE score above 0.30, which applied to 40% of cases, had a significantly diminished 
survival compared with a matched general population (HR 5.51, 95%CI 4.52-6.72, P value <.0001), 
with 5-, 10- and 15-year transplant-free survival rates of 79.7%, 57.4%, 42.5% respectively. Patients 
with a GLOBE score of 0.30 or less (responders) had a life-expectancy comparable with a matched 
general population; the 5-, 10- and 15-year transplant-free survival rates were 98.0%, 92.0%, 82.3% 
respectively (p-value: <.0001) (Figure 3). Non-responders were significantly more often at a late 
stage of disease at baseline than responders (Supplementary Table 4). 
 The performance of the GLOBE score was assessed using the aforementioned threshold. A 
high positive predictive value was found at 5-year follow-up (1057/1084, 98%) and at 10-year follow-
up (588/669, 88%), implying that the probability of reaching an adverse outcome is very low for 
patients identified as a responder. Also a high specificity was found at 5-year follow-up (193/220, 
88%) and 10-year follow-up (328/409, 80%) which means that the majority of patients with an 
adverse outcome were identified as non-responder. Additionally, we found a sensitivity of 65% 
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(1057/1623) at 5-year and 69% at 10-year (588/857) follow-up and a low negative predictive value at 
5-year (193/759, 25%) and at 10-year (328/597, 55%) follow-up. 
       
The performance of the GLOBE score compared with other criteria 
The overall discriminative ability of the GLOBE score was superior in comparison with previously 
proposed stratification tools
9-13
 (Table 3). To quantify the improvement in discriminative ability the 
NRI for both events and non-events in the validation set was calculated.
23
 The percentage of patients 
with an event at 5- and 10-year follow-up that were correctly reclassified with the GLOBE score as 
compared with existing criteria ranged from 3% to 25% and 1% to 22% respectively, and in patients 
without an event at 5- and 10-year follow-up the NRI ranged from -15% to 18% and -14% to 21% 
respectively  (Table 4).     
 
The performance of the GLOBE score among different age groups, disease severity groups and at 
different time points 
Additionally, we created five equal age groups (<45, 45-52, 52-58, 58-66 and ≥66 years), to perform 
an in-depth analysis of the threshold per age group. Patients within these groups were separately 
matched with an age- and sex-matched population and thresholds of -0.52, 0.01, 0.60, 1.01 and 1.69 
respectively were determined. When using these thresholds 70%, 50%, 30%, 20% and 10% 
respectively of patients had a diminished survival compared with a matched population. 
Importantly, this implies that older patients inevitably may derive les impact ultimately from 
additional therapies.  
Within the derivation cohort the performance of the GLOBE score was tested within a 
subgroup of patients with histological early stage PBC (n=673), defined as stage I or II  and a 
subgroup of patients with histological late stage PBC (n=309), defined as stage III or IV. In the early 
stage subgroup 280/1090 (26%) patients had a survival significantly deviating from that of a matched 
population and this were 373/540 (69%) patients in the advanced stage subgroup. In both subgroups 
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the predictive ability of the score was satisfactory with a C statistic of 0.81 (95% CI 0.76-0.86) in the 
early stage subgroup and 0.78 (95% CI 0.74-0.83) in the late stage. Comparable results were found 
when repeating these analyses in the validation cohort; with a C statistic in the early stage (n=448) of 
0.85 (0.79-0.91) and in the late stage (n=212) of 0.79 (0.72-0.86).  
Importantly, the risk score was calculated based on lab values collected 1 y after UDCA 
therapy, but transplant-free survival could still be accurately calculated by the GLOBE score with 
laboratory values collected at 2–5 y after treatment (Supplementary Table 5). 
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DISCUSSION 
 
In this study of over 4000 UDCA treated patients with PBC from across Europe and North America 
we present the GLOBE score, an internationally relevant and validated risk assessment tool, able to 
accurately stratify patients to high and low risk. The score comprises five simple, readily available 
and objective variables: age, bilirubin, albumin, alkaline phosphatase and platelet count. Moreover, 
through robust evaluation and validation we demonstrate appropriate test characteristics in 
subgroups with early and advanced disease. Most importantly, the prognostic ability of the score 
was found to be markedly superior to previously proposed criteria for (non-)response to UDCA. The 
score has utility for patients managed with PBC internationally, as a means to more readily stratify 
risk of adverse outcomes, and hence tailor patient education. In particular, in an era of potential new 
therapies the GLOBE score is better able than current stratification tools to highlight patients at 
greatest need for new therapies. Of further relevance to the health economics of PBC, the GLOBE 
score improves capacity to identify individuals in whom UDCA mono-therapy should be continued, 
with opportunities to de-escalate care back to their primary care provider.  
Previous studies have extensively documented the prognostic importance of the individual 
components of the GLOBE score. In particular, age, bilirubin and albumin have been recognized as 
important predictors of survival in PBC, irrespective of UDCA treatment
7, 8, 25, 26
 In general, age and 
mortality are strongly correlated and not surprisingly age proved to be an independent predictor of 
liver transplantation or death in present study. Serum bilirubin is generally considered the strongest 
and most independent predictor of outcome in PBC,
18, 27-29
 and is a main component of prognostic 
models
25, 30-32
 and response criteria in PBC.
10, 11, 13, 33
 Serum bilirubin levels normally increase 
relatively late in the course of disease. However, its predictive value is not limited to late stage 
disease, as suggested by our previous finding that even in patients with normal levels, prognosis 
improves as levels fall.
18
 Alkaline phosphatase levels are of key importance in establishing the 
diagnosis PBC.
2, 3
 Changes in alkaline phosphatase levels have previously been documented to 
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provide significant prognostic information, both in UDCA treated
9, 10, 12, 13, 18, 34
 and untreated PBC.
18
 
Finally, the platelet count, generally considered as a marker of portal hypertension,
35
 has been 
validated as an independent predictor of outcome in addition to current biochemical response 
criteria.
15, 36
  
Although some of the factors comprising the score, such as bilirubin and albumin, will 
change relatively late in the course of disease, the GLOBE score performed well in patients with early 
stage disease. This is probably largely explained by the well-documented strong predictive 
significance of alkaline phosphatase values, even in cases with normal bilirubin.
18
  
Our score provides improved identification of patients insufficiently responding to UDCA in 
comparison with previously reported criteria (Table 3). As reflected by the high positive predictive 
value, responders to UDCA according to the GLOBE score are at low risk for future adverse events. 
Therefore these patients can reliably be advised to continue with UDCA mono-therapy. The GLOBE 
score also allows more reliable identification of patients likely to have a future unfavourable health 
outcome. Thus, for healthcare providers the GLOBE score provides an improved instrument for 
selecting candidate patients for additional, second-line therapies. The superior performance of our 
score is likely attributable to the effect of dichotomization of every single variable in previously 
proposed response criteria. Dichotomization of continuous variables inevitably will have led to loss 
of predictive ability.
37
 Moreover, age, as a recognized major predictor of survival, was included in our 
score. Importantly, we confirm that younger patients have the potential to benefit more from 
additional PBC therapies than older patients.
14
 Finally, the methodological approach to base the 
score on a prognostic index, corresponding with a continuum of possible outcomes, is an important 
factor explaining improved ability to reliably estimate prognosis using the GLOBE score.  
Other predictors of outcome in PBC have been suggested, including liver histology and 
elastography.
38, 39
 Liver histology has important prognostic meaning,
38
 but in the majority of cases 
liver biopsy is not considered necessary for diagnosis.
3
 Moreover, given other disadvantages, such as 
its invasive character, sampling error and inter-observer variation, liver biopsy is no longer routinely 
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performed in the management of PBC patients. Non-invasive assessment of liver fibrosis with 
transient elastography  is an interesting alternative,
39
 but data supporting this technique as an 
important clinical tool are still limited and further validation is required. Elastography may be less 
suitable for assessing the response to medical treatment, especially after a relatively short duration 
of treatment, as PBC is a slowly progressive disease, suggesting it might take longer before reliably 
detectable changes in liver stiffness will ensue.
4-6
 Biochemical markers are routinely checked during 
yearly check-up of PBC patients, and levels of biochemical variables after a short period of UDCA 
treatment are strongly associated with long-term outcome.
9-13, 18, 34
 Considering the fact that 
biochemical markers are easily obtainable and readily available, they seem more attractive and 
preferable for first-line patient stratification.   
A potential limitation to our study is the use of reference population data originating from 
only one country, namely the Netherlands, for developing the Global PBC Study Group Score. 
However, according to life table data of the World Health Organisation (WHO) life expectancy was 
comparable among the countries involved in this study.
40
 Therefore, this may not be a factor of 
major relevance. Further, we were not able to take into account other laboratory variables of 
potential interest in PBC, such as gamma-GT, IgM, IgG and prothrombin time. Due to the nature of 
our study laboratory data were also not always fully complete, especially when inclusion in the 
original cohort studies occurred more than 15-20 years ago. However, considering the exceptionally 
large dataset, we believe our results are sufficiently robust, as well as notably representative. Finally, 
the reliability of our findings is supported by the validation of the prognostic model in a separate 
population of considerable size. The complex calculation of the GLOBE score has been simplified by 
the development of a web application to improve its usage in clinical practice (www.globalpbc.com).  
In conclusion, we demonstrate that the prognosis of patients with PBC, irrespective of the 
stage of disease, who have been treated with UDCA for one year can be readily determined using a 
de novo derived and validated, risk calculation. Our score performs significantly better than thus far 
proposed criteria for response to UDCA thereby providing internationally representative data to 
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quantify the needs of low- and high-risk patients with PBC. The GLOBE score therefore complements 
efforts to develop and implement a more stratified, evidence-based, approach to the care of 
patients with PBC.   
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FIGURE LEGENDS 
 
Figure 1. Liver transplant-free survival probability.  
Transplant-free survival probability of patients with primary biliary cirrhosis in the derivation cohort 
(N = 2488, solid line) and the validation cohort (N = 1631,dotted line). 
 
Figure 2. Liver transplant-free survival probability of risk groups according to the GLOBE score.  
A). Transplant-free survival probability of 5 predefined risk groups according to percentiles of the 
GLOBE score: (1) <10
th
, (2) 10
th
-40
th
, (3) 40
th
-60
th
, (4) 60
th
-90
th
 and (5) >90
th
, and B). accompanying 
hazard ratios between the risk groups in the derivation (N = 2488, solid line) and validation cohort (N 
= 1631, dotted line).   
 
Figure 3. Liver transplant-free survival probability using a GLOBE score threshold.  
Transplant-free survival probability of patients with a GLOBE score of 0.30 or less compared with an 
age-, sex- and calendar-time matched population for patients within (A) the derivation and (C) the 
validation cohort, and for those with a GLOBE score greater than 0.30 this probability significantly 
deviated for patients within (B) the derivation and (D) the validation cohort.  
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Table 1. Baseline characteristics  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Baseline biopsies (obtained within one year of start of UDCA) were available in 1204/2488 (48%) 
patients of the derivation cohort and in 827/1631 (51%) patients of the validation cohort. 
 Derivation cohort 
(n=2488) 
Validation cohort 
(n=1631) 
Age, years, mean (SD) 54.6 (11.7) 54.8 (11.9) 
Female, n (%) 2253 (90.6%) 1453 (89.1%) 
AMA+, n (%) 2208 (88.7%) 1425 (87.4%) 
Year of diagnosis 1997 (1991-2003) 1998 (1992-2004) 
Year of diagnosis, time frame 1961-2012 1970-2012 
Histological disease stage, n (%)*   
Stage I  336 (27.9%) 237 (28.6%) 
Stage II 337 (28.0%) 211 (25.5%) 
Stage III 171 (14.2%) 125 (15.1%) 
Stage IV 138 (11.5%) 87 (10.5%) 
Not available 222 (18.4%) 167 (20.2%) 
Serum bilirubin (xULN) 0.65 (0.45-1.00) 0.67 (0.45-1.05) 
Serum alkaline phosphatase (xULN) 2.11 (1.37-3.79) 2.16 (1.33-3.78) 
Serum AST (xULN) 1.46 (0.94-2.20) 1.45 (0.94-2.27) 
Serum ALT (xULN) 1.68 (1.05-2.59) 1.63 (1.00-2.67) 
Serum albumin (xLLN) 1.14 (0.15) 1.14 (0.17) 
Platelet count 246 (90) 240 (96) 
AST/ALT ratio 0.90 (0.72-1.16) 0.92 (0.73-1.18) 
APRI 0.60 (0.34-1.01) 0.62 (0.36-1.09) 
   
Laboratory data after one year   
Serum bilirubin (xULN) 0.57 (0.41-0.86) 0.59 (0.41-0.90) 
Serum alkaline phosphatase (xULN) 1.34 (0.93-2.26) 1.36 (0.93-2.25) 
Serum AST (xULN) 0.90 (0.67-1.40) 0.90 (0.67-1.42) 
Serum ALT (xULN) 0.90 (0.60-1.53) 0.90 (0.59-1.47) 
Serum albumin (xLLN) 1.14 (0.15) 1.14 (0.17) 
Plateletcount 237 (90) 237 (96) 
AST/ALT ratio 1.03 (0.79-1.33) 1.03 (0.81-1.33) 
APRI 0.38 (0.25-0.66) 0.39 (0.26-0.72) 
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Table 2. Univariate and multivariable cox regression analysis for liver transplantation or death within the derivation cohort (n=2488) 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: HR, hazard ratio; LLN, lower limit of normal; ULN, upper limit of normal; AST, aspartate aminotransferase; ALT, alanine aminotransferase; 
APRI, AST to Platelet Ratio Index. 
1
A P-value of <0.01 was considered as statistically significant. 
2These biochemical variables were transformed with natural logarithm. 
 Univariate analyses Multivariable analyses
1 
 HR 95% CI P HR 95% CI P 
Age at baseline, per year 1.038 1.030-1.046 <.0001 1.045 1.035-1.056 <.0001 
Male sex 1.913 1.510-2.425 <.0001 - - - 
Bilirubin xULN
2
 3.215 2.903-3.562 <.0001 2.560 2.219-2.952 <.0001 
Alkaline phosphatase xULN
2
 1.929 1.687-2.204 <.0001 1.399 1.175-1.665 .0002 
AST xULN
2
 2.560 2.220-2.952 <.0001 - - - 
ALT xULN
2
 1.401 1.232-1.594 <.0001 - - - 
Albumin xLLN 0.014 0.007-0.028 <.0001 0.104 0.045-0.238 <.0001 
Platelet count (*10
9
/L), per 10 units  0.993 0.992-0.995 <.0001 0.970 0.961-0.990 <.0001 
AST/ALT ratio
2
 2.537 1.998-3.223 <.0001 - - - 
APRI
2
 2.235 1.985-2.518 <.0001 - - - 
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Table 3. Performance of biochemical response criteria and the GLOBE score  
 
 
 
 
 
 
 
 
 
 
a
Response assessed after one year UDCA treatment. Response according to Toronto criteria calculated after 2 years.  
b
After 2 years follow-up 2335/2488 patients of the derivation cohort and 1521/1631 patients of the validation cohort were at risk.    
 
 Derivation cohort (n=2488) Validation cohort (n=1631) 
Criteria
a*
 HR 95% CI P-value C statistic 95% CI HR 95% CI P-value C statistic 95% CI 
Barcelona
9
 1.69 1.39-2.06 <.0001 0.58 0.55-0.61 1.84 1.42-2.38 <.0001 0.57 0.54-0.61 
Paris-1
10
 3.64 3.03-4.36 <.0001 0.69 0.66-0.71 4.61 3.61-5.90 <.0001 0.70 0.67-0.73 
Rotterdam
11
 4.11 3.32-5.08 <.0001 0.69 0.66-0.71 4.10 3.11-5.42 <.0001 0.68 0.65-0.71 
Toronto
12, b
 2.13 1.76-2.56 <.0001 0.61 0.58-0.63 2.46 1.90-3.18 <.0001 0.62 0.59-0.65 
Paris-2
13
 2.82 2.29-3.47 <.0001 0.63 0.61-0.65 2.89 2.17-3.85 <.0001 0.63 0.61-0.66 
GLOBE score - - - 0.81 0.79-0.83 - - - 0.82 0.79-0.84 
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Table 4. Net reclassification improvement of the GLOBE score compared with existing response criteria 
for events and non-events at 5-year follow-up  
 Derivation cohort Validation cohort
 5-year 10-year 5-year 
Criteria
a
 Events NRI
b
 Non-events NRI
b
 Events NRI
b
 Non-events NRI
b
 Events NRI
b
 Non-events NRI
b
 Events NRI
Barcelona 25% 10% 21% 13% 26% 9% 22%
Paris-1 12% -8% 15% -6% 17% -7% 13%
Rotterdam 21% -15% 22% -14% 23% -13% 23%
Toronto 21% 2% 21% 6% 28% 0% 20%
Paris-2 3% 18% 1% 21% 5% 18% 0%
Abbreviation: Net reclassification improvement, NRI 
a
All criteria were calculated after 1 year follow-up except Toronto criteria which was calculated after 2 
years follow-up. 
b
The event NRI and non-event NRI were calculated as following: event NRI = (number of events classified 
up – number of events classified down) / number of events and non-event NRI = (number of non-events 
classified down – number of non-events classified up) / number of non-events.
22
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FIGURE LEGENDS 
 
Supplementary Figure 1. Distribution of the GLOBE score within the derivation and validation cohort 
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TABLES 
 
Supplementary Table 1. Center specific characteristics of the study population.  
 
Derivation cohort Validation cohort 
 
 Year of diagnosis Follow-up  
(years) 
End points  Year of diagnosis 
Follow-up (years) 
End points 
 
N Median (IQR) Median (IQR) Death LTx N Median (IQR) Median (IQR) Death LTx 
USA, 
(Rochester) 
349 2000 1997-2006 4.9 2.6-10.1 70 30 241 2000 1997-2007 4.1 2.1-9.7 32 36 
The 
Netherlands, 
(Nationwide 
cohort) 
515 1998 1992-2005 9.1 4.9-14.6 96 19 323 2000 1994-2006 8.5 4.5-13.1 57 12 
Canada, 
(Toronto) 
301 1999 1994-2003 7.6 4.4-11.4 24 15 228 1999 1995-2004 7.5 4.6-11.7 10 12 
Italy,  
(Padua) 
166 1997 1991-2005 8.0 4.3-14.3 40 2 110 2000 1995-2006 6.1 3.1-11.9 19 2 
UK, 
(Birmingham) 
175 2003 2000-2007 5.7 3.1-9.7 29 27 110 2003 2000-2007 6.8 4.2-10.0 21 14 
French, (Paris) 
221 1988 1986-1993 5.3 2.1-8.8 26 25 127 1987 1985-1992 6.2 2.1-9.2 12 15 
USA, (Dallas) 
191 1993 1990-1996 9.1 7.1-11.7 11 18 135 1993 1991-1996 8.5 6.4-11.5 4 14 
Italy, (Milan, 2 
centers) 
232 1990 1984-1997 8.7 4.7-12.9 39 15 154 1989 1985-1994 8.2 5.0-13.5 29 6 
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Supplementary Table 1 (continued). Center specific characteristics of the study population. 
 
Derivation cohort Validation cohort 
 
 Year of diagnosis Follow-up  
(years) 
End points  Year of diagnosis Follow-up 
(years) 
End points 
 
N Median (IQR) Median (IQR) Death LTx N Median (IQR) Median (IQR) Death LTx 
Spain, 
(Barcelona) 
156 1995 1991-2000 12.3 7.7-16.5 22 16 110 1996 1992-2000 12.2 8.1-16.3 9 7 
Belgium, 
(Leuven) 
95 2000 1992-2006 7.9 3.9-13.1 9 15 41 2004 1995-2009 5.3 2.6-11.1 2 4 
UK,  
(London) 
36 1994 1990-1999 9.0 4.8-13.7 1 4 20 1996 1991-2001 8.8 5.1-11.1 1 3 
Canada, 
(Edmonton) 
30 2004 2001-2006 5.9 4.9-8.3 2 3 23 2003 1995-2006 6.5 3.8-9.2 1 6 
USA, (Seattle) 
21 2008 2002-2010 2.7 1.6-9.5 0 0 9 2008 2006-2010 2.9 1.6-6.2 0 0 
Total 
2488 1997 1991-2003 7.8 4.0-12.1 369 189 1631 1998 1992-2004 7.5 3.8-11.8 197 131 
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Supplementary Table 2. Interactions tested between individual variables of the GLOBE score 
 Bilirubin Albumin Alkaline phosphatase Platelet count 
Age 0.94* 0.25* 0.97* 0.75* 
Bilirubin - 0.54* 0.63* 0.74* 
Albumin - - 0.95* 0.89* 
Alkaline phosphatase - - - 0.03* 
*P values of interaction terms tested in the final multivariable Cox regression model; a P <.01 was 
considered statistically significant  
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Supplementary Table 3. Predicted against observed probability of transplant-free survival in the 
validation cohort (n=1631) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
The predicted transplant-free survival probabilities for each risk group were assessed by first 
applying the GLOBE score of each individual in the validation cohort to the baseline survival estimate 
S0(t) derived from the derivation cohort: SGLOBE SCORE(t) = S0(t) 
exp(GLOBE SCORE)
. Than, the average of SGLOBE 
score(t) across each risk group was calculated.   
2
The observed probabilities are observed from Kaplan-Meier estimation.  
Risk groups according 
to percentiles of the 
GLOBE score  
Years of 
follow-up 
Predicted 
probability
1
 
Observed 
probability
2
  
<10
th
 percentile 3-year 0.993 0.993 
 5-year 0.988 0.993 
 10-year 0.968 0.975 
 15-year 0.943 0.975 
10
th
 – 40
th
 percentiles 3-year 0.982 0.993 
 5-year 0.968 0.985 
 10-year 0.918 0.949 
 15-year 0.857 0.882 
40
th
 – 60
th
 percentiles 3-year 0.965 0.975 
 5-year 0.937 0.956 
 10-year 0.840 0.864 
 15-year 0.732 0.789 
60
th
 – 90
th
 percentiles 3-year 0.915 0.924 
 5-year 0.854 0.854 
 10-year 0.660 0.720 
 15-year 0.484 0.478 
>90
th
 percentiles 3-year 0.617 0.638 
 5-year 0.460 0.474 
 10-year 0.183 0.181 
 15-year 0.067 0.069 
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Supplementary Table 4. Baseline characteristics of responders vs non-responders according to the 
threshold GLOBE  score of 0.30 in the derivation cohort. 
 
 Responders 
(n=1493) 
GLOBE score ≤0.30 
Non-responders 
(n=995) 
GLOBE score >0.30 
 
Age, years, mean (SD) 49.14 (10.47) 57.95 (11.51) <.0001 
Female, n (%) 1395 (94%) 858 (86%) 0.0049 
AMA+, n (%) 1493 894 0.52 
Year of diagnosis, median (IQR) 1998 (1992-2004) 1996 (1989-2002) <.0001 
Year of diagnosis, time frame 1961-2012 1971-2012  
Histological disease stage, n (%) 816 389  <.0001 
Stage I  269 (33%) 67 (17%)  
Stage II 251 (31%) 86 (22%)  
Stage III 88 (11%) 83 (21%)  
Stage IV 61 (7%) 78 (20%)  
Not available 148 (18%) 75 (19%)  
Biochemical disease stage, n (%)   <.0001 
Early stage 1262 (85%) 422 (42%)  
Moderately advanced stage 209 (14%) 410 (41%)  
Advanced stage 22 (1%) 163 (16%)  
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Supplementary Table 5. Predictive performance of the GLOBE score calculated after n years of UDCA 
therapy. 
 Validation cohort  
n=1630 
Follow-up C statistic 95% CI 
1 year 0.82 0.79-0.84 
2 years 0.83 0.80-0.85 
3 years 0.83 0.80-0.85 
4 years 0.83 0.80-0.86 
5 years 0.84 0.81-0.87 
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